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Background: Usher syndrome (USH) is the most common disease causing combined deafness and blindness. It is
predominantly an autosomal recessive genetic disorder with occasionally digenic cases. Molecular diagnosis of USH
patients is important for disease management. Few studies have tried to find the genetic cause of USH in Chinese
patients. This study was designed to determine the mutation spectrum of Chinese USH patients.
Methods: We applied next generation sequencing to characterize the mutation spectrum in 67 independent
Chinese families with at least one member diagnosed with USH. Blood was collected at Peking Union Medical
College Hospital. This cohort is one of the largest USH cohorts reported. We utilized customized panel and whole
exome sequencing, variant analysis, Sanger validation and segregation tests to find disease causing mutations in
these families.
Results: We identified biallelic disease causing mutations in known USH genes in 70 % (49) of our patients.
As has been previously reported, MYO7A is the most frequently mutated gene in our USH type I patients
while USH2A is the most mutated gene in our USH type II patients. In addition, we identify mutations in
CLRN1, DFNB31, GPR98 and PCDH15 for the first time in Chinese USH patients. Together, mutations in CLRN1,
DNFB31, GPR98 and PCDH15 account for 11.4 % of disease in our cohort. Interestingly, although the spectrum
of disease genes is quite similar between our Chinese patient cohort and other patient cohorts from different
(and primarily Caucasian) ethnic backgrounds, the mutations themselves are dramatically different. In particular, 76 %
(52/68) of alleles found in this study have never been previously reported. Interestingly, we observed a
strong enrichment for severe protein truncating mutations expected to have severe functional consequence
on the protein in USH II patients compared to the reported mutation spectrum in RP patients, who often
carry partial protein truncating mutations.
Conclusions: Our study provides the first comprehensive genetic characterization of a large collection of
Chinese USH patients. Up to 90 % of USH patients have disease caused by mutations in known USH disease
genes. By combining NGS-based molecular diagnosis and patient clinical information, a more accurate
diagnosis, prognosis and personalized treatment of USH patients can be achieved.* Correspondence: ruichen@bcm.edu; hrfsui@163.com
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Usher Syndrome (USH) is the most common disease of
combined deafness and blindness. It is characterized by
sensorineural hearing loss (SNHL), retinitis pigmentosa
(RP), and manifests with or without vestibular dysfunc-
tion. Depending on the age of onset, the severity of the ret-
inal and hearing phenotypes and the presence or absence of
vestibular dysfunction, USH is classified into three major
categories. USH I is characterized by congenital deafness
with severe balance problems. USH I patients develop
vision problems in early childhood. USH II patients are
born with moderate to severe hearing loss, normal balance,
and usually develop RP during adolescence. USH III
patients have normal or near normal balance, progressive
hearing loss, and vision problems varying in severity which
usually develop during adolescence [1]. Genetically, USH is
genetically heterogeneous, with 12 known disease genes
and 3 additional loci having been identified so far [1–4].
USH is predominantly a recessive disease, though other
inheritance patterns occur at lower frequency. For instance,
a digenic USH can be caused by simultaneous mutations in
both PCDH15 and CDH23 [1]. In addition, truncation of
PDZD7 has been reported as a modifier of GPR98 and
USH2A mutations [5]. It is also worth noting that muta-
tions in many of the USH genes can also lead to deafness
without a retinal phenotype [6–9].
Given the high clinical and genetic complexity under-
lying USH, molecular screening for mutations in USH
genes significantly improves diagnosis. Next generation
sequencing (NGS) is emerging as a cost-efficient tech-
nology for sequencing a large number of genes [10, 11].
NGS is ideally suited for molecular diagnosis of USH for
two reasons. First, many USH disease genes have many
isoforms with a large number of exons. In total, more
than 400 coding exons have been annotated in known
USH genes. As a result, mutation screening for all cod-
ing exons by Sanger sequencing is cost prohibitive while
NGS is feasible. Second, a large diversity of pathogenic
alleles of various types has been reported and novel muta-
tions are frequent, making array based diagnosis inaccurate.
Indeed, in a recent report a European USH patient cohort
was screened for mutations by Sanger sequencing. Interest-
ingly, 48 % of the alleles identified were novel [12]. The rate
of novel mutations is expected to be even higher in poorly
studied populations like our Chinese cohort. Therefore, a
sequence-based approach is necessary to achieve high diag-
nosis rate.
Although USH patients of European descent have been
under intense investigation [1], only a small number of
studies have been published on Chinese USH cohorts,
each with a no more than 10 cases [13–17]. Mutations in
Chinese USH patients from these studies occurred only
in two genes, MYO7A and USH2A. Furthermore, founder
mutations specific for many ethnic groups have beenidentified. For example, the founder mutation c.8559-
2A > G inUSH2A accounts for 26 % of all Western
Japanese USH patients but was never observed in
Europeans. Similarly, the most prevalent mutation in
European populations, c.2299delG in USH2A, has never
been observed in Asian patients [18, 19]. To gain insight
into the molecular basis of Chinese USH patients we per-
formed comprehensive NGS of all known USH genes in a
cohort of 67 probands and their families. Indeed, our co-
hort has a different mutation spectrum than that of pa-
tients of European descent.
Methods
Clinical diagnosis of USH and sample collection
All subjects were initially enrolled at Peking Union
Medical College Hospital (PUMCH). During their initial
visit, a full medical and family history was recorded, ped-
igrees were drawn, and ophthalmological examinations
were performed. Each patient underwent a standard
ophthalmic examination including best correct visual acu-
ity (BCVA) according to projected Snellen charts, slit-
lamp biomicroscopy, dilated indirect ophthalmoscopy,
fundus photography if possible, and visual field tests
(Octopus,Interzeag, Schlieren, Switzerland). Retinal struc-
ture was examined by optical coherence tomography
(OCT) (Topcon, Tokyo, Japan). Electroretinograms (ERGs)
were performed (RetiPort ERG system, Roland Consult,
Wiesbaden, Germany) using corneal “ERGjet” contact lens
electrodes. The ERG protocol complied with the stan-
dards published by the International Society for Clinical
Electrophysiology of Vision. Auditory examinations
including otoscopic exploration, pure-tone and speech
audiometry were conducted by Otolaryngologists.
The diagnosis of USH was based on previously reported
criteria [20]. Written informed consent was obtained from
all participating individuals or their guardians. Genomic
DNA was isolated from peripheral leukocytes using QIA
amp DNA Blood Midi Kit (QIAGEN, Hilden, Germany)
according to the manufacturer’s protocol. This study was
approved by the Institutional Review Board of PUMCH
and adhered to the tenets of the Declaration of Helsinki
and the Guidance on Sample Collection of Human Genetic
Diseases by the Ministry of Public Health of China.
Design of retinal disease capture panel
A capture panel of retinal disease genes was developed
and assessed by our group [10, 11]. All annotated cod-
ing exons and flanking splicing sites for 9 USH genes
(MYO7A, PCDH15, CDH23, USH1C, USH1G, USH2A,
GPR98, DNFB31, and CLRN1) and one USH modifier
gene PDZD7 were included in the capture design. In
total, the panel included 196 known retinal disease
genes (Additional file 1: Table S1). For all patients
without a positive molecular diagnosis, mutations in
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and ABHD12, were screened by whole exome sequencing.
Whole exome sequencing was performed as described
previously [21].
Panel capture sequencing
About 50 pre-capture libraries were pooled together for
one panel capture reaction. Agilent Hybridization and
Wash Kits were used for panel capture, following the
standard manufacturer’s protocol. Captured libraries were
sequenced on the Illumina HiSeq 2000 as 100-bp paired-
end reads, following the manufacturer's protocols. Whole
exome sequencing library construction, capture and se-
quencing was performed as previously described [21].
Bioinformatics analysis of sequencing results and
pathogenic mutation identification
Sequence data was processed through an automated
pipeline developed in house as previously described
[10, 11]. Briefly, raw reads were mapped to the hg19
reference genome followed by variant calling including
SNPs and indels. Variants were then filtered against
both publicly available databases and internal databases
with a cut off frequency of less than 0.5 % in the general
population. The HGMD professional database (http://
www.biobase-international.com/product/hgmd) and USH
bases (https://grenada.lumc.nl/LOVD2/Usher_montpellier
/USHbases.html) [22] were used to search for known
pathogenic mutations. We utilized a previously described
stepwise strategy to systematically identify the putative
pathogenic mutations for each USH family. Mutations in
9 known USH genes were checked for, in order, known
pathogenic mutations, novel loss-of-function mutations,
and novel missense mutations. In cases where missense
mutations segregated with disease, they were considered
as pathogenic even if their functional predictions were
neutral. We also considered reported digenic inheritance
of PCDH15/CDH23, PDZD7/GPR98 and PDZD7/USH2A.
We only considered monoallelic mutations if they were
reported pathogenic missense mutations, nonsense muta-
tions, frameshift mutation and splice site mutations in
known USH genes. The same prioritizing strategy was
applied to other retinal disease genes and we only picked
mutations that fit the disease model of a gene. Sanger
validation was performed for all putative causal patho-
genic mutations. Segregation tests were performed when
additional family members were available.
Results
Recruitment of 67 USH families and clinical diagnosis
In this study, we recruited a total of 70 patients from 67
unrelated USH families from different regions of China.
This group contained 14 patients diagnosed with USH type
I, 54 patients as USH type II or USH type II-like, 1 patientas USH type III, and 1 patient with an undetermined sub-
type. In most families, the proband was the only affected
member in the family, including three patients from con-
sanguineous marriages (USHsrf2, USHsrf38, and USHsrf56)
(Fig. 1). Two families, USHsrf24 and USHsrf66, have mul-
tiple affected members. In family USbHsrf24, both the
father and the daughter were diagnosed with USH II. As
shown in Fig. 1, the USHsrf66 family is a large family with
five affected members, including USHsrf66, USHsrf68, and
USHsrf59 who were recruited for this study. Detailed clin-
ical information pertaining to these families is included in
Additional file 1: Table S3. All our patients exhibited phe-
notypes consistent with USH syndrome [20]. All patients’
clinical phenotypes are listed in Additional file 1: Table S3,
while representative fundus images and hearing test results
are shown in Fig. 2.
Mutation screening for known USH and other eye disease
genes
A gene capture panel containing196 known retinal dis-
ease genes was developed in our lab and has effectively
identified mutations in known retinal disease genes [10,
11]. We applied this retinal disease gene panel to our
USH patients and excellent coverage was achieved with
an average coverage of 109X for target genes (Additional
file 1: Table S2). On average, 96.8 % of the target region
was sequenced with more than 10X coverage which is
sufficient to call heterozygous mutations.
An in-house automatic variant calling, filtering, and
annotation pipeline was used to analyse the sequen-
cing data. Filtering against multiple public and in-
ternal databases, only rare SNPS and indels (defined
as a frequency < 0.5 % in 20,000 controls) were retained for
each patient. Each variant was further annotated and the
ones that do not affect protein coding were further re-
moved. As a result, on average 15 rare variants in all
known retinal disease genes, including 3 in the USH dis-
ease genes, were identified per patient. The pathogenicity
of these variants was further evaluated as described in the
materials and methods section.
Mutations were identified in 10 out of 14 USH I patients
Biallelic mutations in known USH genes were detected
in 10 USH I patients (Fig. 2a). Consistent with previous
reports, MYO7A was the most frequently mutated gene
with 13 different pathogenic mutations found in 8 patients
(Table 1). Among them, 3 have been previously reported
as pathogenic alleles while the other 10 alleles are novel,
including 3 frameshift mutations, 2 splicing site muta-
tions, 3 nonsense mutations, and 2 missense mutations
(Table 1). Both novel missense alleles, MYO7A: c.
2837 T >G: M946R and MYO7A: c. 5396 T > C: P.L1799P,
are likely to be pathogenic based on the following evi-
dence. First, both are extremely rare in the control
Fig. 1 (See legend on next page.)
Jiang et al. Orphanet Journal of Rare Diseases  (2015) 10:110 Page 4 of 13
(See figure on previous page.)
Fig. 1 Pedigrees of non-simplex and consanguineous families and sample example figures of clinical data. a Pedigrees of non-simplex and
consanguineous families. USH patients are illustrated by squares or circles in black while the unaffected family members are in white. Patients with
DNA sequenced by panel or whole exome sequencing in our project are indicated by an arrow. b Fundus of left eye of USHsrf59 at age 31. The fundus
showed salt and pepper pigmentation variation in the periphery retina and attenuation of the retinal vessels. c OCT of left eye of USHsrf59 at age 31.
OCT showed lack of IS/OS except macula fovea in photoreceptor layer. Her visual acuity is 0.8/0.5 at age 31. This patient was diagnosed with USH II.
Her hearing loss began at age 5 and vision loss began at age 12. d Fundus of right eye of USHsrf66 at age 57. The fundus showed bone spicule
pigmentation variation and attenuation of the retinal vessels. e OCT of left eye of USHsrf66 at age 57. Her visual acuity is 0.06/0.06 at age 57. OCT
showed a thinned retinal pigment epithelium and a photoreceptor layer (lack of IS/OS). This patient was diagnosed with USH II. Her hearing loss
began at age 8 and vision loss began at age 30 with night blindness starting from school age. f Hearing test on left ear of USHsrf66
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lic or our internal variant databases that together contain
around 20,000 individuals. Second, the amino acids M946
and L1799 are highly conserved across vertebrates and all
the way to invertebrates (Additional file 2: Figure S1).
Third, in silico prediction of M946R and L1799P variants
suggests that they are likely to be detrimental (Additional
file 1: Table S6). Finally, both variants segregated with dis-
ease within the families in which they occurred.
Additional putatively pathogenic mutations were identi-
fied in PCHD15 and CLRN1 in this group of USH I pa-
tients. Patient USHsrf8 was found to carry compound
heterozygous mutations in PCDH15, consisting of the novel
frameshift mutation PCDH15:c.1799_1800insTA:p.S600fs
and the novel nonsense mutation PCDH15:c. 2893A >T:
p.R965X (Table 1). Interestingly, patient USHsrf14 had an
unexpected molecular diagnosis because patient USHsrf14
was diagnosed with USH I but has mutations in CLRN1
which have previously been reported to cause mostly USH
III [23]. In one previous case, a patient with USH I was
reported to have a CLRN1 frameshift mutation [24]. To-
gether with our study, this may indicate certain CLRN1
mutations can cause USH I. This patient had severely im-
paired hearing at a very young age and got cochlear im-
plants around age of 6. She experienced poor night vision
and wore glasses before she turned 10. This patient was
found to carry novel nonsense mutation CLRN1:c. 658C >
T:p. R220X and novel missense mutation CLRN1:c. 190G >
A:pG64R, which is predicted to be pathogenic (AdditionalFig. 2 Another sample figure title Summary of mutations identified in USH genfile 1: Table S6). The nonsense mutation is from the
patient’s father while the missense mutation is from the
patient’s mother, and the mutation thus segregated with
disease in the small pedigree.
Mutations were identified in 39 of 54 USH II and atypical
patients
Biallelic mutations were detected in 39 USH II or USH
II-like patients (Table 2), with USH2A mutated in 32
patients, GRP98 mutated in 3 patients, CLRN1 mutated
in 2 patients, MYO7A mutated in 1 patient, and DFNB31
mutated in 1 patient (Fig. 2b).
Consistent with previous reports, we found that
USH2A was the most frequently mutated gene in USH
II patients, accounting for about 60 % (32 out of 54) of
patients in this cohort. A total of 40 different mutations
were identified in USH2A, including 27 novel alleles.
The vast majority of the novel alleles (21/27) are clearly
null mutations, including frameshift, splice site, and
nonsense mutations (Table 2). In addition, we identified
6 novel missense mutations predicted to be pathogenic
(Table 2). It is worth noting that these novel mutations
are mostly private and only two alleles, p.S2251X and
p.1912_1912delfs, were observed in two probands. GPR98
is the second most frequently mutated gene in our USH II
patients, with pathogenic mutations occurring in 3
patients. Two homozygous mutations in USH type III
gene CLRN1 were found in 2 USH II patients. Compound
heterozygous missense variants in USH type I genees. a Genes mutated in USH I patients. b Genes mutated in USH II patients
Table 1 Biallelic mutations in USH genes in USH I patientsa
Patient Gene Type NMID Exon cDNA Amino acid Genotype Patient origin Reference
USHsrf17 MYO7A Splicing NM_001127180 19 c2187 + 1G > Ab c2187 + 1G > A Heterozygous Chinese Novel
MYO7A frameshift NM_001127180 5 c.390_391insCc p.M130fs Heterozygous Chinese Novel
USHsrf22 MYO7A nonsynonymous NM_001127180 17 c.C1969T p.R657W Heterozygous UK [37]
MYO7A nonsynonymous NM_001127180 7 c.C721T p.R241C Heterozygous England, Scoland [38]
USHsrf41 MYO7A frameshift NM_001127180 29 c.3695_3705del p.1232_1235del Heterozygous Chinese Novel
MYO7A stopgain NM_001127180 33 c.G4398A p.W1466X Heterozygous Chinese Novel
USHsrf44 MYO7A nonframeshift NM_001127180 43 c.5766_5768del p.1922_1923del Heterozygous ALL types pathogenic in
dbSNP
MYO7A stopgain NM_001127180 40 c.C5467T p.R1823X Heterozygous Chinese Novel
USHsrf53 MYO7A stopgain NM_001127180 33 c.C4354T p.Q1452X Heterozygous Chinese Novel
MYO7A nonsynonymous NM_001127180 23 c.T2837G p.M946R Heterozygous Chinese Novel
USHsrf56 MYO7A nonframeshift NM_001127180 43 c.5766_5768deld p.1922_1923del Homozygous ALL types pathogenic in
dbSNP
USHsrf61 MYO7A frameshift NM_001127180 29 c.3695_3705del p.1232_1235del Heterozygous Chinese Novel
MYO7A frameshift NM_001127180 32 c.4251delC p.I1417fs Heterozygous Chinese Novel
USHsrf39 MYO7A Splicing NM_001127180 32 c.4323 + 2 T > C c.4323 + 2 T > C Heterozygous Chinese Novel
MYO7A nonsynonymous NM_001127180 40 c.T5396C p.L1799P Heterozygous Chinese Novel
USHsrf8 PCDH15 frameshift NM_001142773 14 c.1799_1800insTA p.S600fs Heterozygous Chinese Novel
PCDH15 stopgain NM_001142773 21 c.A2893T p.R965X Heterozygous Chinese Novel
USHsrf14 CLRN1 stopgain NM_001195794 4 c.C658T p.R220X Heterozygous Chinese Novel
CLRN1 nonsynonymous NM_001195794 1 c.G190A p.G64R Heterozygous Chinese Novel
aUnless stated otherwise, alleles are not found in any of the database we used for control common variants
brs111033280;CLN;PM;LSD
c0.000227 in ESP6500
d1/2184 in 1000 genome
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carries two missense variants c.4951G >A: p.D1651N and
c. 4360G > A: p.V1454I. Both of these variants are absent
in the control database and segregate with disease in the
family (Fig. 3). Novel homozygous splicing site mutation
c.963 + 1G >A in DFNB31 was found in a USH II patient
from a consanguineous family, which was confirmed by
segregation tests.
Patient USHsrf26 was the only patient in our cohort
with USH type III, while patient USHsrf3 that does not
fit well in any Usher subtype. Patient USHsrf3 was a
student in a boarding school for disabled kids. There is
no detailed medical record of him and his guardian, a
teacher, didn’t know his past medical history. The pri-
mary diagnosis of Usher syndrome was reached because
he had hearing problems and a retinal phenotype.
No putative mutations in known USH disease genes
have been found for either of these two patients.
Biallelic mutations in 3 patients were found in retinal
disease genes previously un-associated with USH
We reasoned that mutations in other known retinal
disease genes might account for the clinical phenotypeobserved in some of the patients in our cohort for sev-
eral reasons. First, some of our patients may have a dif-
ferent syndromic disease whose phenotype is similar to
USH. Second, it other retinal disease genes may cause
USH syndrome. Third, the hearing loss and visual defects
could co-occur in one individual as a result of mutations in
multiple genes, one causing eye disease and a second gene
causing hearing defects. Finally, it is possible that only part
of the clinical phenotype of a patient has genetic cause.
To test these hypotheses, we checked whether our pa-
tients bear mutations in other known retinal disease genes.
Interestingly, two patients, USHsrf62 and USHsrf5, were
found to carry mutations in EYS that have been associated
with RP [25]. Patient USHsrf62 is homozygous for a
novel frameshift mutation c.910delT:p.W304fs in EYS
(Additional file 1: Table S5). Patient USHsrf5 carries a
novel frameshift mutation, c.8392delG:p.D2798fs and a
known missense mutation in EYS. Therefore, it is likely
that the RP phenotype in these two patients is due to their
mutations in EYS. As many patients with mutations in EYS
have been reported and none of them showed hearing loss,
it is likely that these patients’ hearing problems are inde-
pendent of the retinal phenotype. We did observe a splice
Table 2 Biallelic mutations in USH genes in USH II patientsa
Patient Gene Type NMID Exon cDNA Amino acid Genotype Patient origin Reference
USHsrf1 USH2A Splicing NM_206933 44 c.8559-2A > G c.8559-2A > G Heterozygous Japanese [31]
USH2A nonsynonymous NM_206933 5 c.G802Ad p.G268R Heterozygous uk [39]
USHsrf2 USH2A stopgain NM_206933 49 c.C9723A p.Y3241X Homozygous Chinese Novel
USHsrf7 USH2A stopgain NM_206933 54 c.C10612T p.R3538X Heterozygous Chinese Novel
USH2A stopgain NM_206933 68 c.C14911T p.R4971X Heterozygous UK [30]
USHsrf9 USH2A Splicing NM_206933 44 c.8559-2A > G c.8559-2A > G Heterozygous Japanese [31]
USH2A nonsynonymous NM_206933 28 c.G5581Ac p.G1861S Heterozygous Chinese Novel
USHsrf10 USH2A frameshift NM_206933 9 c.1589_1590insG p.T530fs Heterozygous Chinese Novel
USH2A frameshift NM_206933 28 c.5735_5736del p.1912_1912del Heterozygous Chinese Novel
USHsrf11 USH2A frameshift NM_206933 2 c.100_101insTe p.R34fs Heterozygous Denmark and
Norway?
[40]
USH2A Splicing NM_206933 44 c.8559-2A > G c.8559-2A > G Heterozygous Japanese [31]
USHsrf18 USH2A frameshift NM_206933 2 c.100_101insTe p.R34fs Heterozygous Denmark and
Norway?
[40]
USH2A nonsynonymous NM_206933 42 c.G8232C p.W2744C Heterozygous Chinese [15]
USHsrf20 USH2A Splicing NM_206933 44 c.8559-2A > G c.8559-2A > G Heterozygous Japanese [31]
USH2A nonsynonymous NM_206933 5 c.G802Ad p.G268R Heterozygous UK [39]
USHsrf21 USH2A frameshift NM_206933 17 c.3420_3423del p.1140_1141del Heterozygous Chinese Novel
USH2A stopgain NM_206933 47 c.G9319T p.E3107X Heterozygous Chinese Novel
USHsrf23 USH2A frameshift NM_206933 63 c.13060_13063del p.4354_4355fsdel Heterozygous Chinese Novel
USH2A frameshift NM_206933 67 c.14667delG p.G4889fs Heterozygous Chinese Novel
USHsrf24 USH2A Splicing NM_206933 8 c.1144-2A > C c.1144-2A > C Heterozygous Chinese Novel
USH2A stopgain NM_206933 35 c.C6752A p.S2251X Heterozygous Chinese Novel
USHsrf25 USH2A stopgain NM_206933 35 c.C6752A p.S2251X Heterozygous Chinese Novel
USH2A nonsynonymous NM_206933 50 c.C9815T p.P3272L Heterozygous Dutch [41]
USHsrf30 USH2A frameshift NM_206933 63 c.12409delA p.R4137fs Heterozygous Chinese Novel
USH2A nonsynonymous NM_206933 13 c.T2802Gb p.C934W Heterozygous Chinese [15]
USHsrf31 USH2A nonsynonymous NM_206933 13 c.T2802Gb p.C934W Homozygous Chinese [15]
USHsrf32 USH2A stopgain NM_206933 48 c.C9469T p.Q3157X Heterozygous Japanese [18]
USH2A nonsynonymous NM_206933 14 c.T2914G p.C972G Heterozygous Chinese Novel
USHsrf33 USH2A Splicing NM_206933 10 c.1644 + 1G > A c.1644 + 1G > A Heterozygous Chinese Novel
USH2A stopgain NM_206933 12 c.1993_1994insT p.K665_R666delinsX Heterozygous Chinese Novel
USHsrf35 USH2A stopgain NM_206933 34 c.G6488A p.W2163X Heterozygous Chinese Novel
USH2A nonsynonymous NM_206933 50 c.G9958T p.G3320C Heterozygous Chinese Novel
USHsrf36 USH2A nonsynonymous NM_206933 6 c.C1000T p.R334W Homozygous all types [40]
USHsrf37 USH2A nonsynonymous NM_206933 40 c.A7492T p.S2498C Heterozygous Chinese Novel
USH2A nonsynonymous NM_206933 6 c.G1048Af p.V350I Heterozygous Chinese Novel
USHsrf45 USH2A Splicing NM_206933 44 c.8559-2A > G c.8559-2A > G Heterozygous Japanese [31]
USH2A stopgain NM_206933 11 c.C1876T p.R626X Heterozygous French Canadian? [42]
USHsrf46 USH2A frameshift NM_206933 2 c.100_101insTe p.R34fs Homozygous Denmark and
Norway?
[40]
USHsrf48 USH2A Splicing NM_206933 44 c.8559-2A > G NA Heterozygous Japanese [40]
USH2A nonsynonymous NM_206933 26 c.G5200C p.G1734R Heterozygous Chinese [43]
USHsrf50 USH2A Splicing NM_206933 44 c.8559-2A > G NA Heterozygous Japanese [16]
USH2A stopgain NM_206933 6 c.T1140A p.Y380X Heterozygous Chinese Novel
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Table 2 Biallelic mutations in USH genes in USH II patientsa (Continued)
USHsrf52 USH2A Splicing NM_206933 44 c.8559-2A > G NA Homozygous Japanese [31]
USH2A nonsynonymous NM_206933 2 c.G206T p.S69I Heterozygous Chinese Novel
USHsrf54 USH2A frameshift NM_206933 4 c.710delT p.F237fs Heterozygous Chinese Novel
USH2A nonsynonymous NM_206933 13 c.T2802G p.C934W Heterozygous Chinese [15]
USHsrf55 USH2A frameshift NM_206933 28 c.5735_5736del p.1912_1912del Heterozygous Chinese Novel
USH2A nonsynonymous NM_206933 42 c.G8232C p.W2744C Heterozygous Chinese [15]
USHsrf59 USH2A frameshift NM_206933 2 c.C100T p.R34X Heterozygous Denmark and
Norway?
[40]
USH2A Splicing NM_206933 44 c.8559-2A > G c.8559-2A > G Heterozygous Japanese [31]
USHsrf60 USH2A frameshift NM_206933 2 c.100_101insTe p.R34fs Heterozygous Denmark and
Norway?
[40]
USH2A Splicing NM_206933 44 c.8559-2A > G c.8559-2A > G Heterozygous Japanese [31]
USHsrf63 USH2A frameshift NM_206933 38 c.7184_7194del p.2395_2398del Heterozygous Chinese Novel
USH2A stopgain NM_206933 48 c.T9453A p.Y3151X Heterozygous Chinese Novel
USHsrf66 USH2A Splicing NM_206933 44 c.8559-2A > G c.8559-2A > G Heterozygous Japanese [31]
USH2A stopgain NM_206933 2 c.C100T p.R34X Heterozygous Denmark and
Norway?
[40]
USHsrf69 USH2A stopgain NM_206933 64 c.C13822T p.R4608X Heterozygous Norway? [39]
USH2A stopgain NM_206933 15 c.G3034T p.E1012X Heterozygous Chinese Novel
USHsrf70 USH2A frameshift NM_206933 33 c.6347_6348insC p.H2116fs Heterozygous Chinese Novel
USH2A stopgain NM_206933 41 c.A7984T p.R2662X Heterozygous Chinese Novel
USHsrf42 GPR98 frameshift NM_032119 55 c.11547delA p.I3849fs Heterozygous Chinese Novel
GPR98 nonsynonymous NM_032119 32 c.G7130A p.R2377Q Heterozygous Chinese Novel
USHsrf49 GPR98 nonsynonymous NM_032119 64 c.T13048C p.S4350P Heterozygous Chinese Novel
GPR98 nonsynonymous NM_032119 7 c.G929A p.G310E Heterozygous Chinese Novel
USHsrf43 GPR98 stopgain NM_032119 32 c.C7006T p.R2336X Heterozygous Chinese Novel
GPR98 frameshift NM_032119 70 c.14451_14452del p.4817_4818del Heterozygous Chinese Novel
USHsrf38 DFNB31 Splicing NM_001173425 4 c.963 + 1G > A c.963 + 1G > A Homozygous Chinese Novel
USHsrf64 CLRN1 nonsynonymous NM_001195794 1 c.G191C p.G64A Homozygous Chinese Novel
USHsrf67 CLRN1 nonsynonymous NM_052995 1 c.C19A p.Q7K Homozygous Chinese Novel
USHsrf40 MYO7A nonsynonymous NM_001127180 37 c.G4951A p.D1651N Heterozygous Chinese Novel
MYO7A nonsynonymous NM_001127180 33 c.G4360A p.V1454I Heterozygous Chinese Novel
aUnless stated otherwise, alleles are not found in any of the database we used for control common variants
b1/2184 in 1000 genome
c0.000227 in ESP6500
drs111033280;CLN;PM;LSD
e1/2184 in 1000 genome
f1/2184 in 1000 genome
Jiang et al. Orphanet Journal of Rare Diseases  (2015) 10:110 Page 8 of 13site mutation and a missense mutation in LOXHD1 in
USHsrf62 in our whole exome sequencing data. Mutations
in this gene are associated with non-syndromic hearing
loss, making it likely that the patient’s visual and auditory
problems have independent genetic origins.
Our molecular diagnosis also suggests that patient
USHsrf40’s hearing loss and RP might be explained by
mutations in multiple genes. This patient was diagnosed
with USH II based on his clinical phenotype. Interest-
ingly, compound heterozygous mutations were identifiedin both MYO7A and CNGA1 (Fig. 3). Patients with mu-
tations in MYO7A exhibited a spectrum of phenotypes
ranging from USH I to USH III to atypical USH consist-
ing of non-syndromic hearing loss without retinal a
phenotype [9, 26, 27]. In contrast, mutations in CNGA1
have only been linked to RP so far [28]. Since patient
USHsrf40 didn’t have a vestibular problem, a phenotype
observed in both USH I and III type patients, it is pos-
sible that the two mutations in MYO7A in USHsrf40
only lead to deafness while mutations in CGNA1 are the
Fig. 3 Double compound heterozygous mutations in patient USHsrf40. Patient USHsrf40 carries compound heterozygous mutations in two genes
MYO7A and CGNA1: two missense mutation in MYO7A and frameshift and missense mutations in CNGA1. Mutations segregate in this family
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idea, mutations in MYO7A identified in this patient were
indeed relatively weak. In particular, one of the missense
variants,MYO7A:c.4360 G >A:p.V1454I, was predicted to
be neutral by all functional prediction tools used except
CADD [29] (Additional file 1: Table S6). Given that the
mutation affects a highly conserved amino acid, was absent
from all control databases and segregates with the disease,
this variant is was likely to be mildly pathogenic.
No mutations were identified in CIB2, ABHD12 and HARS
Three of the known USH disease genes, CIB2, ABHD12
and HARS, were not included in the capture panel. To
achieve a comprehensive screening, we performed whole
exome sequencing (WES) on patients who were negative
for mutations in known USH disease genes after the
target capture sequencing. No mutations were identified
in these three USH genes that were not included in our
panel, indicating that mutations in these three genes are
not major causes of USH in Chinese patients.
USH2A mutation severity determines patient phenotype
We identified 40 distinct USH2A alleles in this study.
Previous studies from multiple groups, including ours,
have already shown that mutations in USH2A can lead
to either USH II or non-syndromic RP [10, 29]. We
compared the USH2A alleles from 32 USH II patients
identified in this paper with a collection of 38 RP pa-
tients whose disease was caused by USH2A mutations
([10] and our unpublished data). The number of obvi-
ously null alleles (including nonsense mutations, splicing
mutations, and frameshift mutations) carried by eachpatient was counted. As shown in Fig. 4, the vast majority
of USH II patients carry at least one null allele (29/32).
Specifically, 17 patients carry two null alleles and 12 USH
II patients carry one null allele. In contrast, among the 38
RP patients, only 2 carry two null alleles and 12 carry one
null allele. Therefore, mutations carried by USH II patients
tend to be more severe than those found in RP patients
(Fisher’s exact test p-value < 0.0001). Indeed, patients with
two severe mutations in USH2A were predominantly USH
II patients (53 % USH II vs 5 % RP) while patients with two
missense mutations were largely RP patients (9 % USH II
vs 63 % RP). Further supporting our observations, the vast
majority of USH2A alleles identified from another pub-
lished USH II patient cohort are null alleles (Fig. 4)
[30]. It is likely that severe disruption of USH2A causes
both hearing and RP phenotypes in most cases, while
milder disruptions to USH2A only cause RP except in
patients with a background or environment predisposed
to hearing loss.
Discussion
In this report, we comprehensively screened 67 unre-
lated USH families for disease causing mutations. This is
the largest Chinese USH cohort molecularly tested to
date. All known USH disease genes as well and other
known retinal disease genes were screened for mutations
using a combination of panel capture and whole exome
sequencing, representing the first NGS based comprehen-
sive molecular characterization of a large Usher patient
cohort. This approach allowed us to obtain accurate esti-
mates of mutation frequency in known USH disease genes
in the Chinese population. Our results reveal a similar but
Fig. 4 USH patients are highly enriched in patients with two severe alleles. Patients with USH2A mutations were classified based on number of
severe alleles (frameshift mutations, splicing site mutations and nonsense mutations). Enrichment of patients with two severe mutations is significant
(Fisher exact test, p-value < 0.0001) in two independent USH patients cohorts (USH patients in this study [30]) compared to that of RP patients
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pared to European patients.
In our cohort, causal mutations were identified in 47
families (49 patients), achieving an overall solving rate of
70 %. This is similar but slightly lower than that of pre-
vious studies on patients of European descent, which
used sanger sequencing of 9 genes to obtain diagnosis
rates of 72 and 85 % [12, 30]. In our patient cohort,
USH2A and MYO7A are the most frequently mutated
genes, accounting for 46 and 12 % patients, respectively.
This rate is similar to the 55 and 14 %, respectively,
observed in a previous study that Sanger sequenced 9
USH genes in 172 ethnically heterogeneous UK patients
who are primarily Caucasian [30]. In addition to these
two most frequently mutated genes, mutations in CDH23,
PCDH15, USH1C, USH1G, GPR98, DBNF31, CLRN1,
CIB2, ABHD12 and HARS have been reported to cause
USH syndrome. However, these 10 genes only each
account for a small percent of the patients and together
account for no more than 20 % [1, 12, 30]. Until now,
patients with mutations in these less frequently mutated
genes have not been reported for Chinese USH patients.
In this cohort, mutations in these genes together account
for about 11.4 % patients. Significantly, we identify the first
Chinese patient(s) with mutations inCLRN1, DFNB31,
GPR98 and PCDH15.
In contrast to the similarity in frequency of mutations
in known USH disease genes between ethnic groups,
many alleles identified in the Chinese patient cohort are
absent from other ethnic groups. For example, in ourstudy, a total of 40 alleles have been identified in USH2A
with 67.5 % being novel alleles. This is striking as a large
number of mutations (>200) have already been reported
for USH2A with much lower rate (40 % and 48 %) of
novel causal alleles identified in studies screened USH
genes in European patients [12, 30]. Since the vast ma-
jority of reported alleles come from studies of patients of
European descent, the allele spectrum in our Chinese
patients differs from that present in current allele data-
bases. This idea is further supported by the observation
that, for the 13 known mutations in USH2A identified in
this study, only 8 alleles were been previously reported
in Caucasians, while the other 5 were exclusively reported
in Chinese or Japanese patients [16, 18, 31]. Furthermore,
strong founder effect has been observed in both ethnic
groups. For example, USH2A:c.2299delG, which is the
most prevalent European mutation and accounts at
approximately 30 % of all European USH2A [19], was not
detected in our patients despite being thoroughly tested.
In contrast, the splice site mutation USH2A:c.8559-2A >
G, which has been previously identified solely in Chinese
and Japanese patients, is the most frequent mutation in
our patient cohort and was observed in 11 patients.
Our study clearly demonstrates that the molecular
basis of USH syndrome is highly heterogeneous in sev-
eral ways. First, although founder mutations have been
identified, the vast majority of the alleles are rare and
each only appears in a small fraction of patients. Indeed,
77 % of the alleles identified in our study are novel. The
large diversity of mutations in USH genes has also been
Jiang et al. Orphanet Journal of Rare Diseases  (2015) 10:110 Page 11 of 13noted in other Middle Eastern populations [32]. With
this in mind, we expect a high rate of novel mutations in
the Chinese population. Second, multiple genes have
been associated with USH syndrome. To date, 15 USH
associated genes have been identified. In our study,
mutations in 6 known USH disease genes were found.
Third, mutations in the same gene can lead to different
clinical phenotypes. For example, CLRN1 mutations
have been associated with USH III [23] while in our
study, 3 patients with CLRN1 mutations exhibit USH I
or USH II. Our study shows CLRN1 causes a broad
spectrum of hearing and retinal phenotypes. Finally, the
same clinical phenotype can be caused by mutations in
multiple genes. For example, one patient in our cohort,
USHsrf40, carries mutations in both MYO7A (c.4951G >
A and c.4360G > A) and CNGA (c.265delC and c.479C >
T) that result in hearing and vision impairment respect-
ively; therefore this patient does not have canonical USH
syndrome. Given this heterogeneity, it is important to com-
bine a patient’s clinical information with their molecular
diagnosis in order to provide patients with better prognoses
and to help match management and treatment strategies
with the patient disease.
Several attempts to establish genotype and phenotype
correlation in USH2A have been reported [33, 34]. None of
these studies identified apparent genotype/phenotype cor-
relations. Similar to previous reports, no apparent geno-
type/phenotype correlations were observed when we cross
referenced the patient’s alleles and their clinical phenotypes.
Interestingly, a strong correlation between he genotype and
phenotype was observed when we compared alleles ob-
tained from our USH cohort and our own and previously
reported RP cohorts. Our study suggests that more severe
loss-of-function mutations in USH2A lead to syndromic
retinopathy. By determining the severity of various USH
mutations we could predict the disease that babies or
fetuses with a given genotype are likely to develop.
In our patient cohort we observed an enrichment of
mono-allelic mutations genetically undiagnosed patients,
particularly in USH2A. For patients where bi-allelic
mutations could not be found, mono-allelic USH2A
nonsense mutations, frameshift and splicing site muta-
tions occurred in 10 out of 54 USH II patients (20 %)
(Additional file 1: Table S4). This is significantly higher
than what is observed in controls, which typically have a
frequency of less than 1 % (internal unpublished data).
This data suggests that a significant portion of USH2A
mutations might be missed by exome capture sequen-
cing. Given that the entire coding region of the USH2A
was well covered by our design, it is likely that the miss-
ing alleles are either in non-coding regions or are struc-
tural rearrangements, such as deletions or inversions
that affect USH2A protein production. Indeed, a recent
study of theUSH2A locus reveals 35 % of USH2Amonoallelic cases can be solved by screening for duplica-
tions, deletions and deep intronic mutations [35]. Thus,
much of the missing heritability in USH could be
achieved as follows. First, we could discover mutations
not previously annotated by improving functional pre-
diction software. An example of this is a recent study of
ABCA4 that demonstrated the effect of synonymous
mutations and splice site modification mutations as a
major cause of Stargardt’s disease [36]. Second, we can use
a compensatory method, such as comparative genomic
hybridization, to detect duplications and deletions. Third,
sequencing gene promoters and other regulatory regions
will allow for the identification of pathogenic regulatory
mutations. The lack of reliable prediction tools and high
throughput experimental assays are the main bottle-
necks in identifying these types of mutations.
In summary, we report the first NGS-based compre-
hensive molecular survey of a large Chinese USH patient
cohort. Our results suggest that up to 90 % of USH
patients are due to mutations in known USH disease
genes when including patients with monoallelic muta-
tions in USH2A. By combining molecular diagnosis and
patient clinical information, a more accurate diagnosis,
prognoses and personalized treatment of individual USH
patients can be achieved.
Conclusions
Our study provides the first comprehensive characterization
of a large collection of Chinese USH patients. Up to 90 %
of USH patients are due to mutations in known USH
disease genes. By combing NGS-based molecular diagnosis
and patient clinical information, a more accurate diagnosis,
prognosis and personalized treatment of USH patients can
be achieved.
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